aging framework

Right then, the field's absolutely buzzing with progress! We're seeing remarkable advances across multiple fronts.

First, the twelve hallmarks of aging framework got a crucial update in 2023 - we've added chronic inflammation, disabled macroautophagy, and dysbiosis to our damage catalog. This gives us even more targets to hit simultaneously.

The really exciting stuff? Combination therapies are proving far more effective than single interventions. We're seeing senolytics like dasatinib plus quercetin clearing out those zombie cells, while NAD+ boosters restore cellular energy. Add in some epigenetic reprogramming factors, and you're attacking multiple damage types at once.

Human trials are accelerating too. The TAME trial with metformin is exploring whether we can target aging itself rather than individual diseases. Several senolytic trials are underway, and NAD+ precursors like NR and NMN are showing promise.

What's particularly encouraging is the shift from merely extending lifespan to extending healthspan - ensuring those extra years are healthy ones. AI integration is accelerating discovery, helping us identify optimal combination strategies.

The key insight remains: aging is an engineering problem. Identify the damage, develop the repairs, apply them systematically. We're not waiting for complete understanding - we're fixing what we can fix now.

With proper funding and focus, I maintain we'll achieve LEV by the 2030s. The breakthroughs are compounding, not linear.